INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,474,531 | -23.9% | 85,900 | -7.5% | 0.59% | -0.3% |
| Q2 2023 | $5,882,428 | +105.0% | 92,900 | +75.3% | 0.59% | +38.9% |
| Q1 2023 | $2,869,950 | -54.4% | 53,000 | -55.5% | 0.42% | -53.2% |
| Q4 2022 | $6,297,480 | -17.4% | 119,000 | -27.4% | 0.91% | +40.0% |
| Q3 2022 | $7,627,000 | -46.3% | 163,900 | -34.2% | 0.65% | -59.5% |
| Q2 2022 | $14,213,000 | +10.6% | 249,000 | +18.6% | 1.60% | +47.6% |
| Q1 2022 | $12,850,000 | – | 210,000 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |